Travelers' Diarrhea

4
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
RIFAXIMINApproved
rifaximin
Unknown Company
oral
Bausch Health
XIFAXANApproved
rifaximin
Bausch Health
oral2010

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
Rifaximin and loperamidePhase 41 trial
Active Trials
NCT00292344CompletedEst. Aug 2005
Sandoz
SandozAustria - Kundl
1 program
1
RifaximinPhase 31 trial
Active Trials
NCT02920242TerminatedEst. May 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthRifaximin and loperamide
SandozRifaximin

Clinical Trials (2)

NCT00292344Bausch HealthRifaximin and loperamide

Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea

Start: Jun 2004Est. completion: Aug 2005
Phase 4Completed
NCT02920242SandozRifaximin

A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

Start: Dec 2016Est. completion: May 2017
Phase 3Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space